Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sun Pharmaceutical Industries Ltd. Capital/Financing Update 2021

Dec 15, 2021

59215_rns_2021-12-15_e2f514a7-e283-4606-81e5-6d320381414c.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

Sun Pharmaceutical Industries Limited SUN HOUSE, CTS i\lo. 201 8/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel .. (91-22) 4324 4324 Fax.: (91 -22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunphanna.com

December 15, 2021

National Stock Exchange of India Limited, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Sandra Kurla Complex, Sandra (East), Mumbai- 400 051

Scrip Symbol: SUNPHARMA

BSE Limited, Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001

Scrip Code: 524715

Sub: Press Release

Dear Sir I Madam,

Please find enclosed herewith our Press Release relating to US FDA approval for generic Amphotericin B Liposome Injection, which we shall be releasing after s~nding this letter to you.

This is for your information and dissemination.

Thanking you,

Yours faithfully, For Sun Pharmaceutical Industries Limited

Ashok I. Bhuta. Compliance Officer Enclosed: As above

Sun Pharmaceutical Industries Limited SUN HOUSE, CTS No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063, India Tel.: (91-22) 4324 4324 Fax.: (91-22) 4324 4343 CIN: L24230GJ1993PLC019050 www.sunpharma.com

FOR IMMEDIATE RELEASE

Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection

Mumbai, India, December 15, 2021: Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" including its subsidiaries and/or associate companies), today announced that one of its wholly-owned subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic Amphotericin B Liposome for Injection, 50 mg/vial Single-Dose Vial. The generic product approval is based on AmBisome® Liposome for Injection, 50 mg/vial as a reference product.

Sun Pharma has been granted Competitive Generic Therapy (CGT) designation by US FDA and being the first approved generic, is eligible for 180 days of CGT exclusivity for the product.

As per October 2021 IQVIA Health data, AmBisome® Liposome for Injection, 50mg/vial had annualized sales of approximately US\$ 136 million in USA.

® - All brand names and trademarks are the property of respective owners

Disclaimer:

Statements in this Document describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the interpretations of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050):

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across 6 continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6-7% of annual revenues in R&D. For further information, please visit www.sunpharma.com & follow us on Twitter@SunPharma_Live.

Contacts

Investors
Nimish Desai
Media
Gaurav Chugh
Tel + 91 22 4324 4324, Ext 2778 Tel + 91 22 4324 4324, Ext 5373
Tel Direct + 91 22 43242778 Tel Direct + 91 22 43245373
Mobile + 91 98203 30182 Mobile + 91 98104 71414
E mail [email protected] E mail [email protected]

Registered Office: SPARC, Tandalja, Vadodara – 390 012, Gujarat, INDIA.